News and Events
Celebrating CCR Careers: Steven Z. Pavletic, M.D., Ph.D.
Steven Z. Pavletic, M.D., Ph.D., is a renowned expert in chronic graft-versus-host disease, a serious late complication that can happen after allogeneic bone marrow transplants. After serving at the NCI for over 20 years, he is now announcing his retirement.
Read MoreNew research identifies a protein essential to maintaining chromosomal stability
Researchers discovered how overproduction of a protein called CENP-A can lead to chromosomal abnormalities, which are found in many types of cancer.
Read MoreNew database of sarcoma cell line data will drive rare cancer research
CCR researchers have developed the largest publicly accessible sarcoma cell line database called Sarcoma CellMinerCDB. The tool merges previously available and new sarcoma cell line data that can be used to identify new therapeutic targets for these cancers.
Read MoreClinical trial researching combination therapy for solid tumors
A trial led by Steven A. Rosenberg, M.D., Ph.D., Chief of the Surgery Branch, is researching white blood cell gene therapy and vaccine therapy for certain metastatic cancers.
Read MoreThree CCR researchers elected to the National Academy of Sciences
Steven A. Rosenberg, M.D, Ph.D., Chief of the Surgery Branch, Giorgio Trinchieri, M.D., Chief of the Laboratory of Integrative Cancer Immunology, and Sandra L. Wolin, M.D., Ph.D., Chief of the RNA Biology Laboratory, were elected as 2024 members of the National Academy of Sciences in recognition of their distinguished and continuing achievements in original research. The Academy is committed to furthering science in America, and its members are outstanding contributors to the international scientific community.
Read MoreClinical trial researching detection methods for multiple myeloma
A trial led by Elizabeth M. Hill, M.D., Assistant Research Physician in the Lymphoid Malignancies Branch, is studying a radiotracer that may be a useful detection method for multiple myeloma.
Read MoreJung-Min Lee elected to the American Society for Clinical Investigation
Jung-Min Lee, M.D., Senior Investigator in the Women’s Malignancies Branch, was elected to the American Society for Clinical Investigation. The organization seeks to support scientific efforts, educational needs and clinical aspirations of physician-scientists to improve the health of all people. Lee was selected for her merit as an internationally recognized expert in ovarian cancer and for being a highly respected clinician and physician-scientist.
Read MoreCCR researchers receive a range of HHS awards
Three CCR researchers received prestigious awards from the Department of Health and Human Services. They are being recognized for their excellence, dedication and achievements in their respective research fields.
Read MoreCCR researchers elected to the Association of American Physicians
Elaine S. Jaffe, M.D., NIH Distinguished Investigator in the Laboratory of Pathology, and Yves Pommier, M.D., Ph.D., Chief of the Developmental Therapeutics Branch, were elected as 2024 members of the Association of American Physicians. The organization seeks to inspire physician-led research across all fields of science and medicine to improve patient health care and the health of Americans.
Read MoreCelebrating CCR Careers: Mark Gilbert, M.D.
Mark Gilbert, M.D., has been a neuro-oncologist for nearly four decades, working to find better treatments for people with rare brain and spine tumors. After nearly a decade at CCR as Chief of the Neuro-Oncology Branch, he is announcing his retirement.
Read MoreNIH researchers develop AI tool with potential to more precisely match cancer drugs to patients
In a proof-of-concept study published on April 18, 2024, in Nature Cancer, CCR researchers have developed an artificial intelligence (AI) tool that uses data from individual cells inside tumors to predict whether a person’s cancer will respond to a specific drug. The team, led by Eytan Ruppin, M.D., Ph.D., Chief of the Cancer Data Science Laboratory, suggests that such single-cell RNA sequencing data could one day be used to help doctors more precisely match cancer patients with drugs that will be effective in treating their cancer.
Read More